DecreasedDBC1Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer

Abstract

PurposeThe deleted in bladder cancer 1 (DBC1) gene is located within chromosome 9 (9q32-33), a chromosomal region that frequently shows loss of heterozygosity in bladder cancer (BC). It is suspected that it acts as a tumor suppressor gene, but its prognostic value remains unclear. The aim of the present study was to investigate the value of DBC1 as a prognostic marker in BC.Materials and MethodsThe expression of DBC1 was determined by real-time polymerase chain reaction analysis in 344 patients with BC (220 non-muscle-invasive BC [NMIBC] and 124 muscle-invasive BC [MIBC]) and in 34 patients with normal bladder mucosa. The results were compared with clinicopathologic parameters, and the prognostic value of DBC1 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model.ResultsDBC1 expression was significantly decreased in patients with MIBC compared with those diagnosed with NMIBC (p=0.010). Patients with aggressive tumor characteristics had lower DBC1 expression levels in NMIBC (each, p<0.05). By multivariate Cox regression analysis, low DBC1 expression was a predictor of progression to MIBC (hazard ratio, 7.104; p=0.013). Kaplan-Meier estimates revealed a significant difference in tumor recurrence, progression to MIBC, and cancer-specific survival depending on the level of DBC1 expression in NMIBC (log-rank test, each, p<0.05).ConclusionsThe expression of DBC1 was associated with tumor aggressiveness, progression to MIBC, and survival in NMIBC. Our results suggest that DBC1 expression can be a useful prognostic marker for patients with NMIBC.

CCAR2 Is Required for Proliferation and Tumor Maintenance in Human Squamous Cell Carcinoma

“…, 2013b; Song and Surh, 2012), resulting in uncertainty whether CCAR2 would serve as a useful predictive biomarker. Some reports have suggested that CCAR2 is reduced in tumors (Shim et al , 2013; Won et al , 2015), consistent with data from Ccar2 − / − mice exhibiting an increase in tumor formation (Qin et al , 2015). This also fits with the established role for CCAR2 in regulating stability of p53 through acetylation (Kim et al , 2008; Zhao et al , 2008) or inhibition of the p53 ubiquitin ligase Mdm2 (Qin et al.…”

Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2

“…Recently, interest has grown in the use of microarray-based gene expression profiling for predicting the survival and outcomes for individual cancer patients ( 6 ). High-throughput microarray technology can be used to investigate the RNA expression levels of hundreds of thousands of genes, and it can provide comprehensive insight for molecular levels of human cancer ( 7 ).…”

Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas

“…Reduced expression of BRINP1 caused by different mechanisms, such as promoter hypermethylation, has been revealed in a number of tumor types including lymphoproliferative malignancies, non-small cell lung carcinomas, and astrocytomas [66–68]. Furthermore, in non-muscle-invasive bladder cancer, lower expression of BRINP1 is associated with unfavorable prognosis [69]. PROM1 is a pentaspan transmembrane glycoprotein that has been described by different research groups as a CSC factor in meningiomas [9, 10, 12, 13].…”